Hot Features
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to id... Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mutant; non-small cell lung; endometrial, cervical, ovarian, and bladder cancer; and diffuse large B-cell lymphoma, as well as various acute myeloid leukemia and myelodysplastic syndrome. The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.53 | -12.441314554 | 4.26 | 4.345 | 3.54 | 150976 | 3.8056928 | CS |
| 4 | -0.505 | -11.9244391972 | 4.235 | 4.59 | 3.54 | 171497 | 4.03699125 | CS |
| 12 | -1.26 | -25.250501002 | 4.99 | 5.59 | 3.54 | 148479 | 4.56168618 | CS |
| 26 | -0.9 | -19.4384449244 | 4.63 | 6.95 | 3.54 | 157947 | 5.08935638 | CS |
| 52 | -0.45 | -10.7655502392 | 4.18 | 6.95 | 3.27 | 158775 | 4.89948927 | CS |
| 156 | -3.77 | -50.2666666667 | 7.5 | 10.25 | 2.7 | 134802 | 5.55315853 | CS |
| 260 | -6.84 | -64.7114474929 | 10.57 | 24.34 | 2.7 | 146108 | 9.28492958 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.